This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, M. Articles by Garber, D. W. Search for Related Content PubMed PubMed Citation Articles by Miller, M. Articles by Garber, D. W.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:2151-2156.)
© 1995 American Heart Association, Inc.

Articles

A Prospective, Randomized Trial of Phenytoin in Nonepileptic Subjects With Reduced HDL Cholesterol

Michael Miller; Rachel G. Burgan; Laura Osterlund; Jere P. Segrest; David W. Garber

From the University of Maryland Medical System, Baltimore (M.M., R.G.B.), and the University of Alabama at Birmingham (L.O., J.P.S., D.W.G.).

Correspondence to David W. Garber, PhD, University of Alabama at Birmingham, DREB Room 630, Birmingham, AL 35294-0012.

Abstract Observational studies have demonstrated a positive association between phenytoin use and HDL cholesterol (HDL-C). Our goal was to determine whether phenytoin raises HDL-C in nonepileptic subjects at risk for coronary artery disease. We performed a double-blind, placebo-controlled, parallel-group study in 41 subjects with reduced levels of HDL-C. Subjects were placed on an American Heart Association Step I diet and were randomized to receive either phenytoin or placebo for 3 months. Serum levels of phenytoin were monitored and adjusted to between 7.5 and 15 µg/mL. Fasting levels of lipids and lipoproteins were determined twice at baseline (weeks -2 and -1) and during the treatment phase of the study (weeks 11 and 12). Compared with dietary baseline, phenytoin-treated subjects experienced significant paired percent increases in total HDL-C (12.4%; P<.01), an effect confined to the HDL₂ subfraction (137%; P<.01). The paired percent increases in HDL-C and HDL₂ levels remained significant after adjustment for placebo (P<.05, P<.025, respectively). There were no significant differences in the paired percent changes from dietary baseline in total cholesterol, triglyceride, or LDL cholesterol levels between placebo and phenytoin-treated groups. The significant paired percent increases in total HDL-C and HDL₂ from dietary baseline suggest a potential role for phenytoin in subjects with reduced levels of HDL-C.

Key Words: cholesterol • phenytoin • humans • HDL

This article has been cited by other articles:

				D. Masson, M. Qatanani, A. L. Sberna, R. Xiao, J. P. Pais de Barros, J. Grober, V. Deckert, A. Athias, P. Gambert, L. Lagrost, et al. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice J. Lipid Res., August 1, 2008; 49(8): 1682 - 1691. [Abstract] [Full Text] [PDF]